Structure via PubChem · Public domain (PubChem)
Niraparib
Sign in to saveAlso known as compound 56 [PMID 19873981], MK 4827, MK-4827, Zejula
chemische Verbindung
Key facts
- Drug.legal_AU
- S4
- Drug.image
- Niraparib.svg
- Drug.image_class
- skin-invert-image
- Drug.caption
- Above: molecular structure of niraparib Below: 3D representation of a niraparib molecule
- Drug.image2
- Niraparib 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Zejula
- Drug.MedlinePlus
- a617007
- Drug.DailyMedID
- Niraparib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XK02
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C19H20N4O
- Molecular weight
- 320.4 g/mol
- IUPAC name
- 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
- SMILES
- C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
- InChIKey
- PCHKPVIQAHNQLW-CQSZACIVSA-N
- XLogP
- 2.2
- Polar surface area
- 72.9 Ų
- H-bond donors
- 2
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2017
- Admin. routes
- oral
- Indications
- ovarian carcinoma, neoplasm, prostate adenocarcinoma, Hereditary breast and ovarian cancer syndrome
via ChEMBL · EBI
Research
986 papers- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2024
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.The New England journal of medicine · 2019
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.The New England journal of medicine · 2016
- Niraparib.2012
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 320.164
Show 7 more facts
- chemical formula
- C₁₉H₂₀N₄O
- canonical SMILES
- C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
- subject has role
- PARP inhibitor
- isomeric SMILES
- NC(=O)C1=CC=CC2=CN(N=C12)C3=CC=C(C=C3)[C@@H]4CCCNC4
- NCI Thesaurus ID
- C80059
- medical condition treated
- ovarian cancer
- Commons category
- Niraparib
Sources (7)
via Wikidata · CC0
Article · Deutsch
Niraparib (Handelsname Zejula; Hersteller Tesaro) ist ein Arzneistoff aus der Gruppe der PARP-Inhibitoren, der in der Behandlung von Ovarialkarzinom (Eierstockkrebs) eingesetzt wird. Die Europäische Kommission (EC) hat im November 2017 die Zulassung für Zejula (Niraparib) in der Europäischen Union (EU) erteilt. Zejula ist der erste in Europa zugelassene orale, einmal täglich einzunehmende Poly (ADP-Ribose)-Polymerase (PARP) 1/2-Inhibitor, für den keine Testung des BRCA-Mutationsstatus oder eine andere Biomarkertestung erforderlich ist. Niraparib wurde im März 2017 von der US-amerikanischen Zulassungsbehörde (FDA) für die USA zugelassen.
Abstract from DBpedia / Wikipedia · CC BY-SA